Chemours (CC) EBITDA Margin (2014 - 2026)

Chemours' EBITDA Margin history runs 13 years deep, the most recent figure standing at 1.88% for Q1 2026.

• On a quarterly basis, EBITDA Margin fell 199.0% year-over-year to 1.88% in Q1 2026; TTM through Mar 2026 was 1.55%, a 600.0% decrease from a year earlier, with the FY2025 full-year figure at 1.1%, down 662.0% from the prior year.
• EBITDA Margin climbed to 1.88% in Q1 2026 per CC's latest filing, from 0.38% in the prior quarter.
• Across five years, EBITDA Margin topped out at 17.23% in Q1 2022 and bottomed at 23.86% in Q2 2023.
• The 5-year median for EBITDA Margin is 3.87% (2025), against an average of 2.91%.
• Across the five-year window, EBITDA Margin tumbled 3519 bps in 2023 and soared 3190 bps in 2024, its largest moves.
• Year by year, EBITDA Margin stood at 0.67% in 2022, then jumped by 35 bps to 0.44% in 2023, then surged by 1123 bps to 4.49% in 2024, then plunged by 108 bps to 0.38% in 2025, then surged by 600 bps to 1.88% in 2026.
• Per Business Quant, the three latest CC EBITDA Margin figures stand at 1.88% (Q1 2026), 0.38% (Q4 2025), and 5.42% (Q3 2025).